Boston, MA43 Active Studies

Erectile Dysfunction Clinical Trials in Boston, MA

Find 43 actively recruiting erectile dysfunction clinical trials in Boston, MA. Connect with local research sites and explore new treatment options.

43
Active Trials
39
Sponsors
12,194
Enrolling

Recruiting Erectile Dysfunction Studies in Boston

RecruitingBoston, MANCT04626635

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

This study is researching an investigational drug called REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors ...

933 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingBoston, MANCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....

787 participants
Eli Lilly and Company
View Study Details
RecruitingBoston, MANCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

727 participants
Immunocore Ltd
View Study Details
RecruitingBoston, MANCT05768139

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with...

720 participants
Eli Lilly and Company
View Study Details
RecruitingBoston, MANCT05417594

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

695 participants
AstraZeneca
View Study Details
RecruitingBoston, MANCT05489211

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Ad...

582 participants
AstraZeneca
View Study Details
RecruitingBoston, MANCT06701903

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Stati...

570 participants
Intra-Cellular Therapies, Inc.
View Study Details
RecruitingBoston, MANCT03526835

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC...

523 participants
Merus N.V.
View Study Details
RecruitingBoston, MANCT06201676

Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients

The goal of this randomized clinical trial is to learn if the use of a low-dose nonsteroidal anti-inflammatory drug (NSAID), ketorolac, reduces the rate of chronic opioid use in orthopaedic polytrauma...

458 participants
Massachusetts General Hospital
View Study Details
RecruitingBoston, MANCT07197827

A Study of YL242 in Subjects With Advanced Solid Tumors

This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors....

424 participants
MediLink Therapeutics (Suzhou) Co., Ltd.
View Study Details
RecruitingBoston, MANCT06998407

Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in pat...

380 participants
Avenzo Therapeutics, Inc.
View Study Details
RecruitingBoston, MANCT05123482

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents...

370 participants
AstraZeneca
View Study Details
RecruitingBoston, MANCT02332668

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cance...

370 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBoston, MANCT05592626

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with ad...

365 participants
Marengo Therapeutics, Inc.
View Study Details
RecruitingBoston, MANCT05081609

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose exp...

345 participants
Ascendis Pharma Oncology Division A/S
View Study Details
RecruitingBoston, MANCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...

316 participants
Simcha IL-18, Inc.
View Study Details
RecruitingBoston, MANCT05434234

A Study of YL201 in Patients With Advanced Solid Tumors

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) follo...

312 participants
MediLink Therapeutics (Suzhou) Co., Ltd.
View Study Details
RecruitingBoston, MANCT05941507

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expa...

300 participants
LigaChem Biosciences, Inc.
View Study Details
RecruitingBoston, MANCT05443126

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)...

265 participants
Ellipses Pharma
View Study Details
RecruitingBoston, MANCT04867837

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

This is a multicentre, prospective, randomised, double-blinded, group-sequential, parallel-group, adaptive design, phase 3 study to demonstrate the haemostatic efficacy and safety of four-factor proth...

260 participants
Octapharma
View Study Details
RecruitingBoston, MANCT03746431

A Phase 1 Study of [225Ac]-FPI-1434 Injection

This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434...

253 participants
Fusion Pharmaceuticals Inc.
View Study Details
RecruitingBoston, MANCT04145622

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. Th...

250 participants
Daiichi Sankyo
View Study Details
RecruitingBoston, MANCT06809595

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama...

250 participants
Mind Medicine, Inc.
View Study Details
RecruitingBoston, MANCT04301765

Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency

This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer...

230 participants
Seattle Institute for Biomedical and Clinical Research
View Study Details
RecruitingBoston, MANCT06795412

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced...

200 participants
Pyxis Oncology, Inc
View Study Details
RecruitingBoston, MANCT06287463

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with a...

140 participants
Deciphera Pharmaceuticals, LLC
View Study Details
RecruitingBoston, MANCT06657222

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To ...

130 participants
Tubulis GmbH
View Study Details
RecruitingBoston, MANCT06343779

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared t...

120 participants
Pharvaris Netherlands B.V.
View Study Details
RecruitingBoston, MANCT06395519

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti...

120 participants
858 Therapeutics, Inc.
View Study Details
RecruitingBoston, MANCT06425926

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary ef...

117 participants
Georgiamune Inc
View Study Details
RecruitingBoston, MANCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors....

115 participants
ModeX Therapeutics, An OPKO Health Company
View Study Details
RecruitingBoston, MANCT05639543

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH)....

80 participants
Intercept Pharmaceuticals
View Study Details
RecruitingBoston, MANCT06056323

A Study of HB0045 Injection in Patients With Advanced Solid Tumors

This is a phase I/II, open-label, multicenter study . During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB00...

71 participants
Shanghai Huaota Biopharmaceutical Co., Ltd.
View Study Details
RecruitingBoston, MANCT04652882

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD....

70 participants
Vanda Pharmaceuticals
View Study Details
RecruitingBoston, MANCT06840483

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breas...

66 participants
BicycleTx Limited
View Study Details
RecruitingBoston, MANCT02934568

Ribociclib (LEE011) Rollover Study for Continued Access

This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-spons...

50 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBoston, MANCT06881992

A Phase 3 Study of Ersodetug in Patients With Tumor-Associated Hyperinsulinism

The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug for treatment of hypoglycemia in patients with Tumor-Associated Hyperinsulinism (tHI)....

48 participants
Rezolute
View Study Details
RecruitingBoston, MANCT06646289

A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis ...

42 participants
Janssen Research & Development, LLC
View Study Details
RecruitingBoston, MANCT05705024

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of...

38 participants
University of Illinois at Chicago
View Study Details
RecruitingBoston, MANCT05934448

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has ...

35 participants
Jennifer Crombie, MD
View Study Details
RecruitingBoston, MANCT06322342

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain t...

24 participants
Reveal Pharmaceuticals Inc.
View Study Details
RecruitingBoston, MANCT04796012

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/r...

23 participants
University of Texas Southwestern Medical Center
View Study Details
RecruitingBoston, MANCT05642455

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

20 participants
Adaptimmune
View Study Details

About Erectile Dysfunction Clinical Trials in Boston

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.

There are currently 43 erectile dysfunction clinical trials recruiting participants in Boston, MA. These studies are seeking a combined 12,194 participants. Research is being sponsored by Regeneron Pharmaceuticals, Eli Lilly and Company, Immunocore Ltd and 36 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Erectile Dysfunction Clinical Trials in Boston — FAQ

Are there erectile dysfunction clinical trials in Boston?

Yes, there are 43 erectile dysfunction clinical trials currently recruiting in Boston, MA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What erectile dysfunction treatments are being tested?

The 43 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.

Data updated March 2, 2026 from ClinicalTrials.gov